Despite what were generally viewed as a solid set of second-quarter 2007 results, Anglo-Swedish pharmaceutical major AstraZeneca revealed a second restructuring initiative (on top of 3,300 job cuts announced earlier this year (Marketletter February 12) which, involving 4,300 more posts in sales, marketing, business infrastructure and R&D and costing an estimated $1.6 billion, will deliver annual benefits in excess of $900.0 million by 2010.
On the day of the results, July 27, the firm's stock fell 3.1% to L25.92, despite chief executive David Brennan raising the full-year earnings forecast to $3.90-$4.04 per share, from $3.80-$4.05. However, this should be seen in the context of a severe market slump, as the FTSE 100 saw its largest one-day decline in five years, plunging 3.15% on that day.
Earnings fall 10%, hit by MedImmune buy
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze